Recombinant proteins as therapeutic compounds in clinical oncology;Rekombinante proteine als Therapeutika in der klinischen Onkologie

Therapeutische Umschau

Volumn 68, Issue 11, 2011, Pages 618-630

  Fey, Martin F ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD20 ANTIBODY; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; RITUXIMAB; TRASTUZUMAB;

ARTICLE; ATYPICAL CHRONIC MYELOID LEUKEMIA; B CELL LYMPHOMA; BREAST CANCER; CANCER PATIENT; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HUMAN; IN VITRO STUDY; ONCOLOGY; STOMACH CANCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERONS; LEUKEMIA; LYMPHOMA; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 80455162265     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930/a000222     Document Type: Article

References (41)

1. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10: 317-327.
2. Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anticancer Drugs 2002; 13: S3-S10.
3. Ghielmini M, Schmitz SF, Cogliatti S, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103: 4416-23.
4. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2010; 377: 42-51.
5. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-23.
6. Martinelli G, Hsu Schmitz SF, Utiger U et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28: 4480-4484.
7. Coiffier B, Thieblemont C, Van Den Neste E et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adult., Blood. 2010;116:2040-5.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 2001; 344: 783-92.
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New Engl J Med 2005; 353: 1659-72.
10. Romond EH, Perez EA, Bryant B et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med 2005; 353: 1673-84.
11. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97.
12. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-17.
13. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-65.
14. Lynch TJ, Patel T, Dreisbach L Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010;28:911-7.
15. Pirker R, Pereira JR, Szczesna A, Cetuximab plus chemotherapy in patients with advanced non-smallcell lung cancer (FLEX): an open-label randomised phase III trial Lancet. 2009;373:1525-31.
16. Bonner JA, Harari PM, Giralt J, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-78.
17. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients. A meta-analysis. JAMA 2011; 305:487-494.
18. Ambühl I. 7 Fragen an Roche-CEO Severin Schwan. Nehmen Sie Roche-Medis? BLICK 2010; Ausgabe 23. Juli; 3.
19. Ocaña A, Amir E, Vera F, Eisenhauer EA, Tannock IF. Addition of bevacizumab to chemotherapy for treatment of solid tumours: similar results but different conclusions. J Clin Oncol 2011; 29: 254-256.
20. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
21. Saltz L, Clarke S, Diaz-Rubio E et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first line therapy in metastatic colo-rectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
22. Allegra C, Yothers G, O'Connell MJ et al. Phase III Trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2010; 29: 11-16.
23. Tappenden P, Jones R, Paisley S, Carroll C. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 2007; 43: 2487-2494.
24. Miller KD, Chap LI, Homes FSA et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
25. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-76.
26. Dedes KJ, Matter-Walstra K, Schwenkglenks M, Pestalozzi B, Fink D, Brauchli P, Szucs TD. Bevacizumab inn combination with paclitaxel for HER-2 negative meta static breast cancer: an economic evaluation. Eur J Cancer 2009; 45: 1397-1406.
27. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 2006; 355: 2542-2550.
28. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009; 27: 1227-34.
29. Egg G. http://de.wikipedia.org/w/index.php?title=Gottfried_Egg&action=edit§ion=1.
30. Robert NJ, Diéras V, Glaspy J et al: RIBBON-1: randomized, doubleblind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growthfactor receptor-2 negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-60.
31. Burstein H. Bevacizumab for advanced breast cancer: all tied up with a ribbon? J Clin Oncol. 2011; 29: 1232-5.
32. Goldman JM. Treatment strategies for CML. Best Pract Res Clin Haematol. 2009; 22: 303-13.
33. Grever MR, Lozanski G. Modern strategies for hairy cell leukemia. J Clin Oncol. 2011; 29: 583-90.
34. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010; 363: 2511-21.
35. Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist. 2011; 16 Suppl 2: 45-50.
36. Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G; ESMO Guidelines Working Group. Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5: v194-v197.
37. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010; 102: 493-501.
38. Greil R, Psenak O, Roila F; ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol. 2008; 19 Suppl 2: ii116-ii118.
39. Engert A, Josting A, Haverkamp H, et al. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 2010; 28: 2239-45.
40. Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or Darbepoetin for patients with cancer--metaanalysis based on individual patient data. Cochrane Database Syst Rev. 2009; (3): CD007303.
41. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis- stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009; 373: 1532-1542.